CLL
Haematology · 2008–2025
31decisions
9medicines
20carried consumer input
175individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| acalabrutinib Treatment of previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in combination with venetoclax as a fixed duration… | Nov 2025 | Deferred | input received Lymphoma Australia · Rare Cancers Australia |
| acalabrutinib Treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), as monotherapy or in combination with… | Jul 2023 | Recommended with restriction | input received Rare Cancers Australia |
| acalabrutinib Relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (rrCLL/SLL). This submission requested amendments to the Risk Share Arrangement… | Mar 2023 | Not recommended | none received |
| acalabrutinib Treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), who are considered unsuitable for… | Dec 2022 | Not recommended | 15 individuals Lymphoma Australia · Leukaemia Foundation |
| ibrutinib Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), for use in combination with venetoclax in fit patients. | Dec 2022 | Not recommended | 16 individuals Lymphoma Australia · Leukaemia Foundation |
| acalabrutinib Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients considered unsuitable for treatment with a purine… | Jul 2020 | Not recommended | 13 individuals Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| venetoclax Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients with coexisting conditions who are inappropriate for… | Jul 2020 | Recommended with restriction | 13 individuals Leukaemia Foundation |
| acalabrutinib Treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) considered unsuitable for treatment… | Mar 2020 | Recommended with restriction | 9 individuals Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia |
| venetoclax Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients with coexisting conditions who are inappropriate for… | Mar 2020 | Not recommended | 8 individuals Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| ibrutinib First-line treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients with deletion 17p (del17p), demonstrated by fluorescence in… | Nov 2019 | Recommended with restriction | 8 individuals |
| obinutuzumab Treatment of chronic lymphocytic leukaemia (CLL) in previously untreated patients with comorbidities who are inappropriate for fludarabine-based… | Jul 2018 | Recommended with restriction | none received |
| venetoclax Relapsed or refractory chronic lymphocytic leukaemia (CLL) in patients considered unsuitable for treatment or retreatment with a purine analogue, in… | Nov 2018 | Recommended with restriction | 1 individuals |
| venetoclax Treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) in patients who have failed a kinase inhibitor (third-line treatment). | Jul 2017 | Recommended with restriction | 2 individuals |
| rituximab Treatment of patients with CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chemotherapy. | Mar 2017 | Recommended with restriction | none received |
| venetoclax Relapsed/refractory chronic lymphocytic leukaemia (CLL) in patients with 17p deletion/TP53 mutation or patients with highly refractory disease. | Mar 2017 | Deferred | 40 individuals |
| ibrutinib First-line treatment of chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) in previously untreated unfit patients unsuitable for… | Nov 2017 | Not recommended | 4 individuals |
| venetoclax Treatment of relapsed or refractory chronic lymphocytic leukaemia (R/R CLL) in patients who have failed a kinase inhibitor. | Nov 2017 | Recommended with restriction | input received Lymphoma Australia |
| idelalisib Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) that has relapsed or is refractory after at least one prior therapy, in patients who… | Jul 2016 | Recommended with restriction | none received |
| ibrutinib Second-line therapy in patients with chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) deemed unfit for further treatment with a purine… | Mar 2016 | Deferred | input received |
| idelalisib Treatment of relapsed/refractory chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL) in combination with rituximab in patients inappropriate… | Mar 2016 | Deferred | none received |
| ibrutinib Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have relapsed or are refractory to at least one prior therapy and are… | Nov 2016 | Recommended with restriction | none received |
| ibrutinib Treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in patients who have received at least one prior… | Jul 2015 | Not recommended | 29 individuals Lymphoma Australia |
| idelalisib Second-line treatment of chronic lymphocytic leukaemia (CLL) in patients with progressive disease despite previous treatment, specifically those for whom… | Mar 2015 | Not recommended | 5 individuals Lymphoma Australia |
| obinutuzumab Treatment of chronic lymphocytic leukaemia (CLL) in previously untreated unfit elderly patients with comorbidities, in combination with chlorambucil. | Mar 2015 | Recommended with restriction | 6 individuals |
| idelalisib Second-line treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in patients who are relapsed or refractory after at least one… | Nov 2015 | Deferred | 6 individuals |
| obinutuzumab Treatment of chronic lymphocytic leukaemia (CLL) in previously untreated patients with comorbidities, in combination with chlorambucil. | Jul 2014 | Not recommended | input received Lymphoma Australia · Medical Oncology Group |
| ofatumumab Treatment of previously untreated CD20 positive chronic lymphocytic leukaemia (CLL) as first-line therapy in combination with chlorambucil for patients… | Nov 2014 | Not recommended | none received |
| rituximab Treatment of CD20 positive, chronic lymphocytic leukaemia (CLL) in combination with chemotherapy. | Mar 2010 | Deferred | no section in document |
| rituximab CD20 positive chronic lymphocytic leukaemia in combination with chemotherapy (first-line and relapsed/refractory settings). | Nov 2010 | Recommended with restriction | no section in document |
| fludarabine phosphate Treatment of B-cell chronic lymphocytic leukaemia in combination with cyclophosphamide in patients with advanced disease (Binet Stage B or C) or evidence of… | Mar 2008 | Recommended with restriction | no section in document |
| pegfilgrastim Secondary prophylaxis of neutropenia or prolonged severe neutropenia for patients with chronic lymphocytic leukaemia (CLL) being treated with fludarabine and… | Nov 2008 | Recommended with restriction | no section in document |
Who spoke
Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia · Medical Oncology Group
What the PBS pays
$416M in government benefit over 2024–25, across 178,698 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ofatumumab | $93.3M |
| ibrutinib | $85.2M |
| venetoclax | $77.2M |
| acalabrutinib | $72.9M |
| obinutuzumab | $57.6M |
| rituximab | $23.9M |
| pegfilgrastim | $4.3M |
| idelalisib | $1.3M |
| fludarabine phosphate | $0.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 21 technologies for this condition, recommending 13 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| pirtobrutinibPirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor | TA1173 | recommended restricted | 2026-07 |
| venetoclaxVenetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA1119 | recommended restricted | 2026-01 |
| zanubrutinibZanubrutinib for treating chronic lymphocytic leukaemia | TA931 | recommended restricted | 2023-11 |
| ibrutinibIbrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | recommended restricted | 2023-05 |
| duvelisibDuvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | terminated | 2022-07 |
| venetoclaxVenetoclax for treating chronic lymphocytic leukaemia | TA796 | recommended | 2022-06 |
| ibrutinibIbrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | terminated | 2021-05 |
| ibrutinibIbrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | terminated | 2021-05 |
| acalabrutinibAcalabrutinib for treating chronic lymphocytic leukaemia | TA689 | recommended restricted | 2021-04 |
| venetoclaxVenetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | recommended restricted | 2019-02 |
| idelalisibIdelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | terminated | 2017-08 |
| ibrutinibIbrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | terminated | 2017-07 |
Showing the 12 most recent of 21.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 20 of 27 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.